<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Shares of Biogen Inc. BIIB, -2.13% tumbled 2.2% in premarket trading on Friday after the company disclosed in a securities filing that it received a civil investigative demand from the Federal Trade Commission and an inquiry from the Securities and Exchange Commission in relation to Aduhelm, its new Alzheimer’s disease drug. The SEC inquiry is requesting information about the sites that administer the drug, the regulatory approval, and Biogen’s marketing for the therapy, the company said.
...read full article on Market Watch
